NCT04302324: Phase 2: Daratumumab, Clarithromycin, Pomalidomide And Dex RRMM - D-ClaPd
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM
NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study
NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)
AMaRC 19-02 - BelaCarD - Phase I/II - Study of combination belantamab maf, carfilzomib, Dex RRMM
NCT04430894: Phase 2: KRDI in Transplant-Eligible MM
NCT04483739: Phase 3: EMN 24 - Isa-KRd vs KRd New Multiple Myeloma Eligible for ASCT - IsKia TRIAL
NCT04052880 : Phase 2 - SubQ Dara + Dose-Atten. Bortezomib, Lenalidomide, Dex New MM >70 years
NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)
NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard Regimens NDMM
NCT04131309: Phase 2: EMN 22 - Daratumumab Monotherapy in Stage 3B Light Chain (AL) Amyloidosis
NCT04045795: Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04096066: Phase 3: EMN 20 - A Trial That Compare Two Treatments TIE - NDMM - KRd Vs Rd
NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in TIE NDMM
NCT03896737: Phase 2: EMN 18 - Dara-VCd VS VTd Then Maintenance With Ixazomib (IXA) or IXA-Dara
NCT04091126: Phase 1 - Belantamab Mafodotin + Standard of Care New Multiple Myeloma (DREAMM 9) NDMM
NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM
NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies - RRMM Myeloma